Abstract TRAIL/Apo-2L induces rapid apoptosis of a variety of tumor cell lines. A family of tumor necrosis factor receptorrelated molecules have been identified as receptors for TRAIL. Herein, we report the identification of another member of the TRAIL receptor family, TRUNDD (TRAIL receptor with a truncated death domain). The TRUNDD transcript was detected in multiple human tissues. TRUNDD is highly homologous to all known TRAIL receptors and has an extracellular TRAILbinding domain but lacks a functional intracellular death domain and does not induce apoptosis. Consistent with an inhibitory role, ectopic expression of TRUNDD attenuated TRAIL-induced apoptosis in mammalian cells.
Introduction
Apoptosis, or programmed cell death, is an intrinsic cell suicide mechanism of fundamental importance to development and homeostasis in all multicellular organisms [1] . Members of the tumor necrosis factor (TNF) ligand family, TNFK and FasL are well-studied physiologic activators of apoptosis and play an important role in in£ammatory and immune responses [2, 3] . Recently, an additional cytotoxic ligand termed TRAIL/Apo-2L was characterized [4, 5] . TRAIL is expressed in a variety of human tissues and induces apoptosis in many transformed cell lines. Three receptors for TRAIL have been identi¢ed (Fig. 4) [6^12]. DR4 and DR5 are signalling receptors and fully capable of engaging the death pathway. Previously described death receptors, including TNFR1, Fas and DR3, contain a cytoplasmic death domain that binds to the death domain-containing adapter molecule FADD [13] . In turn, FADD recruits and activates the apical death protease designated caspase-8. This initiates a proteolytic cascade resulting in cleavage of death substrates and eventual demise of the cell [14] . Surprisingly, DR4 (TRAIL-R1) and DR5 (TRAIL-R2), despite containing a death domain, induce caspase-dependent apoptosis independent of FADD, suggesting the existence of another death domain-containing adapter molecule [6^8,12] . The third receptor, TRID (DcR1/TRAIL-R3/LIT), is a non-signalling decoy receptor that is GPI (glycosyl-phosphotidylinositol)-linked to the cell surface and antagonizes TRAIL-induced apoptosis [7, 8, 11] . DR4 and DR5 are expressed in many human tissues and cancer cell lines.
Remarkably, the decoy receptor (TRID) is di¡erentially expressed: easily detectable in normal human tissues, but not in most tumor cell lines, consistent with a protective role in normal tissues. In keeping with this hypothesis, overexpression of TRID protects mammalian cells from TRAIL-induced apoptosis. Collectively, the data suggest that TRID/DcR1 may play a protective role that allows normal tissues to withstand the potential cytotoxic e¡ect of TRAIL.
Here we report the identi¢cation and characterization of another TRAIL receptor, designated TRUNDD (see below). TRUNDD is highly related to existing members of the TRAIL receptor family and binds TRAIL. Unlike DR4 and DR5, TRUNDD lacks a functional death domain. Ectopic expression of TRUNDD attenuates TRAIL-induced apoptosis, in keeping with a role as a dominant negative receptor.
Materials and methods

Construction of mammalian expression vectors
To facilitate detection, TRUNDD (amino acids 56^386) was cloned into pCMV1FLAG (IBI Kodak) as an in-frame fusion to the signal sequence and FLAG-epitope tag encoded by the vector. The cDNA encoding the extracellular domain of TRUNDD (amino acids 56^210) was obtained by PCR and subcloned into a modi¢ed pCMV1FLAG vector that allowed for in-frame fusion with the Fc portion of human IgG. DR4-Fc, TNFR1-Fc, Fc, soluble TRAIL and TNFK expression constructs have been described previously [6] .
Northern blot analysis
Human multiple tissue Northern blots (Clontech) were probed with an internal fragment of TRUNDD cDNA according to the manufacturer's instructions.
Preparation of proteins and in vitro binding assays
Receptor-Fc fusions and soluble ligands were prepared and in vitro binding performed as previously described [6, 7] .
Cell death blocking assays
Blocking assays using receptor-Fc fusions were carried out as described [6, 7] .
Results
Molecular cloning and identi¢cation of TRUNDD as a
novel TNF receptor Homology searching of EST (expressed sequence tag) databases with the DR5 sequence and subsequent library screening revealed a novel cDNA clone that was identi¢ed in four di¡erent cDNA libraries. Its open reading frame encoded a protein of 386 amino acids. Protein sequence comparison analysis revealed the molecule to be a member of the TNF receptor family possessing signi¢cant homology to DR4, DR5 and TRID/DcR1 (60^70% amino acid identity) (Fig. 1) . A long putative signal sequence was present at the amino-terminus (amino acids 1^55) and the mature protein was predicted to begin at amino acid 56 (Ala) [15] . Like DR4, DR5 and TRID/DcR1, its extracellular domain (amino acids 56^210) contained two cysteine-rich motifs characteristic of the TNF receptor family [16] . A transmembrane domain was present between amino acids 211 and 230. The cytoplasmic domain, interestingly, contained only a truncated death domain. Thus, this novel receptor was designated TRUNDD (TRAIL receptor with a truncated death domain).
Tissue distribution of TRUNDD transcript
To examine the tissue distribution of TRUNDD, Northern blot analysis was performed. A single transcript was detected in multiple human tissues at varying levels of expression (Fig.  2) . PCR analysis did not reveal the existence of transcripts that may encode an intact death domain (not shown).
TRUNDD is a TRAIL receptor
Since the entire sequence of TRUNDD, especially the ex- (Fig. 3A) . Corroborating this ability to bind TRAIL was the ¢nding that TRUNDD-Fc, like DR4-Fc, could e¤ciently block TRAILinduced apoptosis (Fig. 3B) . Cells were stained with DAPI and examined as described [6] . The data (mean þ S.D.) shown are the percentage of apoptotic nuclei among total nuclei counted (n = 3). C: TRUNDD protects cells from TRAIL-induced apoptosis. HeLa cells were transfected with TRUNDD, CrmA expression construct or vector alone together with a L-galactosidase reporter construct. Twenty-four hours later, TRAIL was added as indicated. Four hours later, cells were ¢xed and stained with 5-bromo-4-chloro-3-indoxyl-L-galactopyranoside and examined microscopically as described [6] .
TRUNDD antagonizes TRAIL signalling in mammalian cells
In keeping with TRUNDD possessing a truncated nonfunctional death domain (Fig. 1) , its overexpression did not induce cell death in mammalian cells (not shown), rather, as might be expected, it could act as a dominant negative receptor antagonizing TRAIL-induced apoptosis (Fig. 3C) . Therefore, ectopic expression of TRUNDD, like that of the decoy receptor TRID substantially attenuated TRAIL-induced cell death, suggesting that TRUNDD may function to antagonize TRAIL signalling.
Discussion
TRAIL is a newly identi¢ed cytotoxic ligand that belongs to the TNF family and rapidly induces apoptosis in a wide variety of tumor cell lines. Unlike Fas ligand, which is predominantly expressed in activated T cells, natural killer cells and at sites of`immune privilege' including the cornea and testis [17] , TRAIL transcripts are constitutively expressed and detectable in a variety of human tissues. Thus, TRAIL must not be injurious to most normal tissues in vivo. Recently, a family of TRAIL receptors have been identi¢ed (Fig. 4) 
